Literature DB >> 19544391

Thrombotic thrombocytopenic purpura in childhood.

Maria C Bouw1, Natasja Dors, Heleen van Ommen, Nicole L Ramakers-van Woerden.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disease, especially in childhood, and has a high mortality rate in the absence of appropriate treatment. It is characterised by microangiopathic haemolytic anaemia and consumptive thrombocytopenia. TTP may be difficult to distinguish from haemolytic uraemic syndrome (HUS) because of similar clinical manifestations and laboratory findings. In the past, TTP and HUS have often been considered to represent variable expressions of a single entity. Our increased understanding of the pathogenesis of TTP has in turn resulted in significant improvements in its treatment and outcomes. Several immunomodulating agents are currently being used with variable outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544391     DOI: 10.1002/pbc.22094

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Authors:  Sabrina Mariani; Silvia M Trisolini; Saveria Capria; Maria L Moleti; Marta Chisini; Giancarlo Ferrazza; Mahnaz Shafii Bafti; Maria A Limongiello; Eleonora Miulli; Flora Peyvandi; Robin Foà; Anna M Testi
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

2.  Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.

Authors:  Parameswaran Narayanan; Aparna Jayaraman; Rashi S Rustagi; S Mahadevan; Sreejith Parameswaran
Journal:  Int J Hematol       Date:  2012-05-03       Impact factor: 2.490

3.  Case of TTP with cerebral infarct secondary to platelet transfusion.

Authors:  Sushil P Tripathi; Anand S Deshpande; Sandhya Khadse; Rajesh K Kulkarni
Journal:  Indian J Pediatr       Date:  2010-09-30       Impact factor: 1.967

4.  Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.

Authors:  Johannes G Krabbe; Evelien W M Kemna; Annuska L M Strunk; Pieter A Jobse; P A Kramer; L D Dikkeschei; L P W J van den Heuvel; Rob Fijnheer; Leo F Verdonck
Journal:  Int J Hematol       Date:  2015-08-13       Impact factor: 2.490

5.  Acquired thrombotic thrombocytopenic purpura in children: a single institution experience.

Authors:  Somasundaram Jayabose; Theodore S Nowicki; Julie Dunbar; Oya Levendoglu-Tugal; Mehmet F Ozkaynak; Claudio Sandoval
Journal:  Indian J Pediatr       Date:  2012-12-21       Impact factor: 1.967

6.  Autoimmune polyglandular syndrome type 3c with ectodermal dysplasia, immune deficiency and hemolytic-uremic syndrome.

Authors:  Mithat Büyükçelik; Mehmet Keskin; Özlem Keskin; Ali Bay; Beltinge Demircioğlu Kılıç; Yılmaz Kor; M Arda Kılınç; Ayşe Balat
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014

7.  Thrombotic microangiopathies.

Authors:  Mohamed Radhi; Shannon L Carpenter
Journal:  ISRN Hematol       Date:  2012-07-25

8.  Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report.

Authors:  Koki Mise; Yoshifumi Ubara; Masanori Matsumoto; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Tatsuya Suwabe; Junichi Hoshino; Naoki Sawa; Kenichi Ohashi; Koichi Kokame; Toshiyuki Miyata; Yoshihiro Fujimura; Kenmei Takaichi
Journal:  BMC Nephrol       Date:  2013-07-20       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.